Previous studies have suggested that defective immune responses in early life may be related to the immaturity of neonatal antigen-presenting cells. To test this hypothesis, we assessed the capacity of neonatal dendritic cells (DC) to prime and polarize in vitro human naive antigenspeci®c T cells. We report that mature cord blood DC ef®ciently prime an oligoclonal population of antigen-speci®c CD8 T cells, capable of cytolytic activity and IFN-g secretion. In contrast, cells primed by immature cord blood DC do not acquire cytolytic activity and secrete lower amounts of IFN-g. Upon priming by either immature or mature DC, neonatal T cells acquire markers of activation and differentiation towards effector-memory cells. Our results demonstrate that, if appropriately activated, neonatal DC can prime ef®cient cytotoxic T lymphocyte (CTL) responses. Furthermore, these ®ndings have important implications for the development of vaccine strategies in early life and for the reconstitution of a functional CTL repertoire after bone marrow transplantation.
Introduction
Neonates and young children show higher morbidity and mortality rates from infectious diseases than adults. The higher susceptibility of neonates to pathogens as well as their poor responses to vaccines has been related to the immaturity of the neonatal immune system. The mechanisms underlying this immaturity are still unclear. It has been shown that neonatal T cells weakly proliferate in response to anti-CD3 stimulation, and have T h 2-biased responses, lower up-regulation of CD40 ligand (CD40L) upon activation and limited cytotoxic activity (1) . In addition, studies on virus-speci®c cytotoxic T lymphocytes (CTL) indicate that CD8 responses are reduced in numbers in neonates as compared to adults and cells secrete less IFN-g (2±4). However, in the presence of strong adjuvants or co-stimulatory signals, neonatal CD4 and CD8 T cells are capable of adult-level responses (5±10). The reduced ability of young infants to develop T h and CTL responses could be due to the immaturity of dendritic cells (DC) that are the main antigen-presenting cells, unique in their ability to ef®ciently prime and polarize naive CD4 and CD8 cells (11) . Indeed, it has been reported that human neonatal monocyte-derived DC have defective production of IL-12 and expression of costimulatory molecules, which may account for the T h 2 bias and the inef®cient T cell stimulatory capacity (12±16). However, other investigators have differentiated functional and mature DC from human cord blood progenitors (17±19), and it has been recently shown that mouse neonatal DC are capable of activating CTL responses both in vitro and in vivo (20) . However, the analysis of human antigen-speci®c CTL priming by cord blood DC has been hampered by the low frequencies of naive T cells. To address this question we set up an in vitro priming model, which we have previously used to expand naive cells from adult blood (21, 22) . We report that human neonatal DC ef®ciently prime naive melan-A-speci®c CD8 + T cells, capable of cytolytic activity and IFN-g secretion. This observation has important implications for vaccination in early life and for the reconstitution of the CTL repertoire after bone marrow transplantation. In addition, our results provide a cellular mechanism to account for the recently reported in utero expansion of Trypanosma cruzi-and human cytomegalovirus (HCMV)-speci®c CTL responses (5, 23) .
Methods

Cell lines and cultures
The medium used throughout was RPMI 1640 supplemented with 2 mM L-glutamine, 1% non-essential amino acids, 1% pyruvate, 50 mg/ml kanamycin, 5 Q 10 ±5 M 2-mercaptoethanol (Gibco) and 10% FCS (Hyclone) or 5% pooled human serum AB + (UK National Blood Service). JY is an HLA-A2 + lymphoblastoid cell line. Melanoma lines Na8 (HLA-A2 + , melan-A ± ) and HBL (HLA-A2 + , melan-A + ) were a gift of Dr Elisabetta Padovan (Kantonspital, Basel, Switzerland). Recombinant human IL-2 and IL-4 were produced in our laboratory as described (24) .
Peptides and tetramers
Melan-A 26±35 ELAGIGILTV is an analogue of the 26±35 epitope with an improved HLA-A2 binding af®nity (25) . Peptides were purchased from Genosys (Sigma) and were puri®ed by HPLC. Melan-A/HLA-A2 tetrameric complexes were synthesized as previously described (26, 27) . Tetramers were tested against positive CTL clones and background levels of staining (<0.02%) were de®ned by staining the peripheral blood mononuclear cells (PBMC) of HLA-A2 ± healthy donors.
Generation and stimulation of DC
Cord blood samples were obtained from the John Radcliffe Hospital maternity unit, upon written consent and approval by the ethical committee. Samples were screened for HLA-A2 expression by FACS analysis. Monocytes were puri®ed by positive selection using anti-CD14-conjugated magnetic microbeads (Miltenyi). The recovered cells were >95% CD14 + as determined by¯ow cytometry with the anti-CD14 antibody TIB228 (ATCC, Rockville, MD). DC were generated as previously described (28) by culturing monocytes in RPMI/ 10% FCS supplemented with 50 ng/ml granulocyte macrophage colony stimulating factor (Leucomax; Novartis Pharma) and 1000 U/ml IL-4 for 5 days; 5% human serum was used instead of FCS in some experiments, but we did not observe any qualitative or quantitative difference in the priming experiments. Cells (3 Q 10 5 /ml) were stimulated by addition of either 1 mg/ml lipopolysaccharide (LPS; from Salmonella abortus equi; Sigma), mock transfected or CD40L-transfected J558 cells [at a 1:5 ratio; provided by P. Lane, Birmingham, UK (29) ]. The CD14 ± fraction was frozen and thawed on the day of the in vitro priming, a few hours before addition to the autologous DC.
T cell priming
DC were pulsed for 3 h with melan-A 26±35 peptide in serumfree medium. Cells were thoroughly washed and incubated with the autologous CD14 ± fraction at a 1:5 ratio in RPMI/5% human serum. Recombinant human IL-2 was added from day 4 to 7 at 10 U/ml. Cells were then expanded with 500 U/ml IL-2 and analyzed at day 10±15.
FACS analysis
Cells were stained in PBS with phycoerythrin (PE)-or allophycocyanin (APC)-labelled melan-A tetramer at 37°C for 20 min, washed at room temperature and incubated on ice with one of the following antibodies: CD8±FITC (Dako), CD8± PerCP (Becton Dickinson), 2B4±FITC (Immunotech), CD8± APC, CD27±FITC, CD45RO±APC, CD45RA±FITC, CD62L±PE, CLA±FITC, CCR7±FITC, CD95 FITC, CD38±APC, class II±FITC and CD28±APC (all from PharMingen); TCR-BV-speci®c antibodies were purchased from Serotec. The samples were analysed on a FACSCalibur (Becton Dickinson) using CellQuest Software. Lymphocytes were gated according to FSC/SSC pro®le and dead cells were excluded by staining with propidium iodide (Sigma).
Expression of melan-A and HLA-A2 was tested using mouse mAb A103 (Novocastra) and BB7.2 (ATCC) respectively, followed by a PE-conjugated af®nity puri®ed goat anti-mouse antibody (Southern Biotechnology Associates).
For intracellular cytokine detection, 10 6 cells were labelled with melan-A tetramer and subsequently stimulated with 20 mM melan-A peptide in RPMI/10% FCS or left unstimulated (30) . Control cells were either unstimulated or treated with 10 ±6 M phorbol myristate acetate (PMA; Sigma) and 0.5 mM iono- 
Cytokine determination
The concentration of IL-12 p75 and p40 in DC supernatants was measured by ELISA (PharMingen). The sensitivity of the assay was 400 pg/ml.
Spectratyping and CDR3 size analysis
CD8 + T cells were positively selected with MACS beads (Miltenyi), with a purity >95% as assessed by¯ow cytometry. Total RNA was extracted from 3 Q 10 6 CD8 + cells in guanidine thiocyanate buffer (RNA-Bee; Biogenesis). The cDNA was then prepared with MMLV reverse transcriptase (Invitrogen) as previously described (31) .
The nomenclature of BV and the BV-or BC-speci®c primers used has been previously described (32, 33) . The 24 PCR reactions for each cDNA were performed according to Garderet et al. (32) . Ampli®cation products were labelled in an extension reaction, so-called run-off reaction, using a BCspeci®c Fam-¯uorescent probe. The¯uorescent run-off products, together with a Tamra-¯uorescent DNA weight marker (Genescan 500; Applied Biosystems), were loaded on sequence gel in an automated DNA sequencer (Perkin Elmer). CDR3 sizes and¯uorescent intensities were analysed with Genescan software (Perkin Elmer).
Cytolytic activity
Cytolytic activity was assessed using a Cr-release assay. JY EBV or melanoma cells were labelled with 51 Cr for 90 min at 37°C and washed twice. Labelled cells were peptide pulsed for 1 h, washed and added (5000 cells/well) to graded numbers of CD8 + puri®ed effector cells. CD8 + cells were puri®ed from the in vitro priming with Miltenyi CD8 microbeads according to the manufacturer's instructions. Chromium release was measured in the supernatant, which was harvested after 5 h of incubation at 37°C. Total release was determined in the presence of 5% Triton X-100. The percent speci®c lysis was calculated as follows: 100 Q (experimental ± spontaneous release)/(total ± spontaneous release). Each value was calculated as the average of triplicates.
Results
Melan-A tetramer + CTL precursors detectable in newborn blood can be ef®ciently primed by autologous DC To assess the ability of human neonatal DC to prime antigenspeci®c CD8 + T cells we used as a model antigen melan-A/ Class II  CD40  CD83  CD80  CD86  CD1a  CD38  ICAM-1   Immature  336  51  20  8  65  230  281  31  184  J558L-(mock)  298  42  17  16  70  252  306  31  244  LPS  727  69  25  90  125  477  282  201  386  J558L-CD40L  815  97  32  77  128  549  267  52  548 Cord blood DC were plated at 400,000/ml and surface marker expression (expressed as mean¯uorescence values) was analysed at day 6, after 36 h of maturation. One representative donor out of ®ve is shown. Fig. 2 . Ef®cient expansion of melan-A tetramer + cells from newborn PBMC by autologous DC. Immature (top panels), LPS-matured (middle panels) or CD40L-matured cord blood DC (bottom panels) were pulsed with 10 mg/ml melan-A 26±35 peptide and incubated with autologous peripheral blood lymphocytes at a 1:5 ratio. After 10 days, cultures were stained with melan-A tetramer±APC and CD8± PerCP and the percentages of CD8 + tetramer + cells are shown. One representative experiment of four is shown.
MART1, a melanoma antigen which encodes for the HLA-A*0201-restricted immunodominant epitope 26±35 (34) . We have previously reported that melan-A tetramer + cells can be detected in the peripheral blood of most healthy blood donors (35, 36) . These cells have the characteristics of naive cells, both functionally and at the molecular level (37) , and can be ef®ciently primed only by professional antigen-presenting cells, such as mature DC (21) . This large pool of antigenspeci®c T cells is already detectable in newborns (37) and we found melan-A tetramer + cells in all HLA-A2 + newborns tested, with frequencies ranging from 0.02 to 0.12%, while all HLA-A2 ± newborns had frequencies below the threshold of 0.02% (Fig. 1) . These cells were CCR7 + , CD27 + , CD45RA + , CD45RO ± , consistent with their naive phenotype [data not shown and (37)].
Since recent studies indicate that neonatal DC are less ef®cient than their adult counterpart in stimulating allogeneic T cells (12±14,16) we investigated whether melan-A tetramer + cells could be primed by autologous cord blood DC as observed in adult donors (21) . The phenotype of monocytederived cord blood DC used for these experiments, before and after maturation with LPS and CD40L, is shown in Table 1 . As shown in Fig. 2 , at high peptide dose, melan-A tetramer + cells were expanded by both immature and mature cord blood DC, the most potent stimulus being CD40L-matured DC, followed by LPS-matured cells. In contrast, when pulsed with lower concentrations of melan-A 26±35 peptide (10 ng/ml), mature DC were 20-fold more ef®cient than immature DC in expanding antigen-speci®c CTL (data not shown). Melan-Aprimed CTL acquired markers of activation and a phenotype similar to effector cells at an intermediate stage of differentiation (38) (Fig. 3A) : they became CD45RO + , CD95 + , 2B4 + and mostly HLA class II + , while they remained CD38 + and CD27 + . CCR7 and CD28 expression was lost on most of the cells. There was no expression of the inhibitory receptors DX9, DX31, CD94/NKG2A, ILT2 and CD158 (data not shown). When primed by CD40L-matured cord blood DC, 22% of the cells expressed CLA and 39% CD62L (Fig. 3B) , homing receptors for in¯amed skin, whose expression is known to be IL-12 dependent (39,40). Although we have observed similar expansions of melan-A speci®c CTL upon priming by mature adult DCs, the latter induced higher percentages of CD62L and CLA expression (21) . As previously reported (12) this difference may be accounted for by the 4±6 times lower secretion of IL-12 p75 by CD40L-matured cord blood DC, as compared to adult DC, in spite of similar amounts of IL-12 p40 (data not shown).
All together, our results demonstrate that when appropriately activated cord blood DC can be powerful antigenpresenting cells.
Functional analysis of melan-A tetramer + CTL primed by cord blood DC
To assess the antigen responsiveness of the tetramer + cells, cord blood DC-primed cultures were stimulated with melan-A 26±35 peptide in a 6-h assay. As shown in Fig. 4(A) , melan-A tetramer + CTL mainly released IFN-g and low levels of TNF-a, showing a type I polarization pattern. The percentages of IFN-g-secreting cells and the level of the cytokine increased after priming by CD40-matured cord blood DC, as observed with adult DC. Tetramer + CTL did not secrete IL-4, IL-10, IL-13 or IL-2 ( Fig. 4A and data not shown) in any of the experiments, not even when primed by immature cord blood DC. To address the type of polarization induced in the entire population, the cytokine pro®le was analysed in response to PMA and ionomycin. Upon priming by immature and LPS-matured cord blood DC, CD8 + cells mainly released IFN-g and low levels of TNF-a (Fig. 4B ). CD8 ± cells secreted IL-2, IL-4, IL-13 and minimal amounts of IL-10, in addition to IFN-g and TNF-a (Fig. 4B and data not shown) . CD40L-matured cord blood DC induced a strong type I polarization, both of the CD8 ± and CD8 + cells.
The cytolytic activity of melan-A tetramer + CTL was assessed against an HLA-A2 + EBV-B cell line and melanoma lines expressing or not the melan-A antigen. As shown in Fig. 5 , CTL primed by immature cord blood DC did not acquire cytolytic activity against peptide-pulsed EBV-B cells, despite high numbers of antigen-speci®c cells (Fig. 5A) . In contrast, cells primed by mature cord blood DC were highly cytolytic and recognized both peptide-pulsed EBV-B cells and melan-A + melanoma cells (Fig. 5B and D) .
Clonal composition of melan-A tetramer + CTL primed by cord blood DC
We determined the usage of TCR BV chains of melan-A tetramer + CTL by spectratype analysis of newborn CD8 + T cells unprimed, primed by unpulsed or pulsed CD40L-matured cord blood DC (Fig. 6A) . As previously described (32), unprimed CD8 + T cells showed a Gaussian distribution of TCR CDR3 length within all BV families (Fig. 6A and data not  shown) . The pro®le of CD8 + T cells primed by unpulsed CD40L DC showed some expansions in certain BV families, compatible with the strong stimulatory capacity of these cells. In contrast, important oligoclonal expansions of CD8 + T cells expressing BV 3, 7 and 16 were observed upon priming by pulsed CD40L DC (Fig. 6A, cf. left, middle and right panels) . The magnitude of these expansions and the size of the CDR3 regions are different from those observed upon priming by unpulsed DC, clearly showing a speci®c T cell response to the melan-A peptide. The speci®city of the oligoclonal expansion was con®rmed by FACS analysis of the same cultures, using BV-speci®c antibodies combined with melan-A tetramer staining (Fig. 6B) .
Discussion
The immaturity of the neonatal immune system has been considered the major obstacle to successful vaccinations in early life and may account for the higher susceptibility of newborns to infectious diseases (41) . It is still unclear whether the cause of such immaturity depends on intrinsic T cell defects or is mainly due to the nature and quality of antigen presentation (1, 42) . As DC are the most potent antigenpresenting cells we investigated whether human cord blood DC could prime functional antigen-speci®c CTL. Experiments were carried out to assess the expansion and activation of melan-A-speci®c T cells in an in vitro priming model that we have previously used for adult DC (21) . Melan-A is a melanoma antigen which encodes for the HLA-A*0201-restricted immunodominant epitope 26±35 (34) . In contrast to the low frequency of most antigen-speci®c T cells in the preimmune repertoire, up to 1:1000 naive CD8 T cells from A2 individuals speci®cally bind melan-A tetramers (35) . Because of the unusual high precursor frequency, up to date this represents the only naive antigen-speci®c T cell repertoire accessible to direct analysis in humans. It has been unequivocally demonstrated by cellular and molecular methods that melan-A precursors are truly naive cells (35± 37) . This large pool of T cells speci®c for a self-antigen is generated by thymic output of a high number of precursors (37) and this has been explained by the existence of largely cross-reactive subsets of naive CD8 T cells displaying multiple speci®cities (43) .
We showed that mature cord blood DC ef®ciently primed melan-A speci®c T cells, which acquired markers of activated cells and were capable of cytolytic activity towards peptidepulsed targets and tumour cells. In contrast, cells primed by immature cord blood DC did not acquire cytolytic activity, despite expression of activation markers. We con®rmed the ®ndings that cord blood DC secrete less bioactive IL-12, as compared to adult DC (data not shown), and this may explain the lower CLA and CD62L expression observed in cells primed by cord blood DC. Indeed, the expression of these homing receptors is known to be IL-12 dependent (21, 39, 40) .
It is generally believed that neonates are more prone to T h 2 immune responses, although CTL and T h 1 responses can be elicited using strong known type I adjuvants (8,44±46) . We have observed a strong type I polarization of CD8 cells primed by CD40L-matured cord blood DC, and lower levels of IFN-g and TNF-a when cells were primed by immature cord blood DC. In contrast, CD8 ± cells secreted both T h 1 and T h 2 cytokines when primed by immature or LPS cord blood DC, but a strong T h 1 polarization was induced by CD40L cord blood DC. These results suggest that although cord blood DC secrete lower levels of bioactive IL-12, this may be suf®cient to elicit type I immune responses (47) or, alternatively, other cytokines may be responsible for T cell polarization in our in vitro system. By spectratype analysis we observed an oligoclonal expansion of melan-A tetramer + CTL primed by cord blood DC, hence con®rming and extending previous results obtained in melanoma patients (48, 49) .
The demonstration that mature cord blood DC can ef®ciently expand functional CTL in vitro provides a powerful strategy to support immune reconstitution of individual antigen speci®-cities (i.e. HCMV CTL) after cord blood transplantation. Moreover, understanding the dynamics of DC±T cell interactions is of fundamental importance in improving the success rates of cord blood transplantation and further reducing the risk of graft versus host disease, e.g. by promoting the expansion of T regulatory cells (50) .
Altogether, our results suggest that the weak CTL responses observed in young infants may not be due to an intrinsic defect in the antigen-presenting cells nor in the T cells. Neonatal T cells may have more stringent requirements for co-stimulatory signals than adult T cells (1); however, when appropriately activated, neonatal DC can prime ef®cient CTL and T h 1 responses (20, 44) . With regard to this, and in agreement with the study by Hermann on T. cruzi-infected newborns (5), we have recently observed that fetuses infected in utero with HCMV develop a mature and functional CD8 T cell response (23) . It has been demonstrated that CD4 help is required for the generation of long-lived CTL responses (51). Since we have observed that HCMV-speci®c CTL present in newborn after in utero infection persist throughout the ®rst year of life (A. Marchant, in preparation), it is likely that cord blood CD4 + T cells are capable of providing T cell help for the generation of CD8 + memory responses. The challenge for the future relies in identifying adjuvants and delivery systems that allow ef®cient neonatal DC activation and migration to achieve optimal DC±T cell interactions in vivo. 
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